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ABSTRACT
Objective Depression and anxiety are not uncommon in
Rheumatoid arthritis (RA). It is increasingly recognised that
they are associated with high disease activity and worse
disease outcomes. We aimed to examine the frequency of
depression and anxiety in an early RA inception cohort and
to explore associations with disease-related measures.
Methods The Scottish Early Rheumatoid Arthritis inception
cohort recruited newly diagnosed RA patients followed-up
6-monthly. Anxiety and depression were assessed using the
hospital anxiety and depression scale. Associations with
demographic characteristics and disease-related measures
were examined at baseline, 6 months and 12 months.
Results 848 RA patients were included. The prevalence of
anxiety and depression at baseline was 19.0% and 12.2%,
respectively. Depression and anxiety scores correlated with
DAS28 at all time-points (all p<0.0001). In multivariable
linear regression, anxiety score at baseline was associated
with younger age and Health Assessment Questionnaire
(HAQ) score. Anxiety scores at 6 months and 12 months
were associated with low body mass index (BMI), baseline
anxiety score and current patient global score and HAQ.
Depression score at baseline was associated with younger
age, being single and HAQ, while depression scores at 6
months and 12 months were associated with male gender
(only at 6 months), baseline anxiety and depression scores
and current patient global score, HAQ and C-reactive protein
(CRP) levels.
Conclusion Depression and anxiety are associated with
disease activity, worse functional status and other variables
in early RA. There is a close relationship between CRP and
depression but not anxiety.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflam-
matory arthritis with both musculoskeletal and
systemic features. RA is associated with several
physical (eg, cardiovascular) and psychological
comorbidities and it is increasingly recognised
that depression and anxiety are associated with
high disease activity, worse disease outcomes
and decreased quality of life.1–6 Most studies
investigating the association of RA with depres-
sion and anxiety are cross-sectional and per-
formed in patients with established RA of
several years’ duration2 4 and/or in patients
having received treatment for RA.1 3 The fre-
quency and relationship of psychological fac-
tors in early RA has been less studied and may
differ from established RA. Here, we examine
longitudinally the frequency of depression and
anxiety in a large inception cohort of early RA
patients and the relationship with demographic
characteristics and disease-related measures.
METHODS
Cohort description
The Scottish Early Rheumatoid Arthritis
(SERA) inception cohort7 prospectively
recruited patients with new-onset RA (ACR-
EULAR 2010 criteria) presenting to secondary-
care rheumatology centres across Scotland
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Key messages
What is already known about this subject
► Depression is not uncommon in rheumatoid arthritis (RA).
► Depression is associated with disease activity and
worse disease outcomes in established RA.
What does this study add
► There is a close relationship of CRPwith depression in RA.
► In early RA, depression and anxiety are common, display
an improving trend over time and associatewith disease
activity and worse functional status and outcome.
How might this impact on clinical practice or
future developments?
► Clinicians should be aware that anxiety and
depression are common in early RA and that while
treating RA properly appears to help anxiety and
depression, this may not be sufficient.
Rheumatoid arthritis
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between 2011 and 2015. Participants were treated by their
usual rheumatology team as per standard clinical practice.
Assessments were recorded at the baseline visit (within
6 months of their diagnosis) and then at 6 months and
12 months follow-up visits. A range of pre-specified fea-
tures were recorded at the baseline visit and then at
6-monthly follow-up visits. These included demographic
(age, gender, body mass index (BMI), current alcohol
consumption, smoking, employment and marital status),
clinical (tender and swollen joint counts, patient global
assessment visual analogue scale (PGA-VAS) for disease
activity, treatment being received), laboratory (Erythrocyte
Sedimentation Rate (ESR), C-reactive protein (CRP),
Rheumatoid factor (RF) and anti-cyclic citrullinated pep-
tides (anti-CCP) status) parameters and disease-related
indices (Disease activity score-28 (DAS28) and Health
Assessment questionnaire (HAQ)—higher HAQmeaning
greater disability). The authors assert that all procedures
contributing to this work comply with the ethical standards
of the relevant national and institutional committees on
human experimentation and with the Helsinki Declara-
tion of 1975, as revised in 2008. All procedures involving
human subjects/patients were approved by the West of
Scotland Research Ethics Committee (Reference 10/
S0704/20). Written informed consent was obtained from
all participants.
Study design
The Hospital Anxiety and Depression Scale (HADS) was
completed by SERA participants at each visit. As has been
previously suggested,8 anxiety and depression were ana-
lysed separately each having a score between 0 and 21.
The ‘change’ of various scores and parameters (depres-
sion score, anxiety score, DAS28, CRP) was the difference
between final and baseline values. Results were analysed
as continuous variables except when determining the
frequency of depression or anxiety. For these, variables
were analysed as categorical, using established cut-off
scores of ≥11 for probable cases of anxiety and/or
depression.8 HADS was also recorded for age-matched
and sex-matched individuals (n=58) with similar genetic
background who were included as healthy volunteers in
SERA cohort. As previously described,7 these were friends
of relatives of the RA patients participated in the study.
Statistics
Univariable analyses were performed at baseline,
6months and 12 months. Two-sided Fisher’s exact and
Mann-Whitney U tests were used to compare categorical
and continuous characteristics, respectively. Wilcoxon
matched paired test was used for paired continuous
observations. Spearman’s rank correlation coefficient
was used for correlations. Benjamini-Hochberg correc-
tion was applied for multiple-comparison correction for
a false discovery rate of 0.25. Cronbach’s alpha test was
used to measure internal consistency for depression and
anxiety scales. Multivariable linear regression was per-
formed using the anxiety and depression scores as
dependent variables, and as independent variables the
features recorded for the participants (see cohort
description). These were: demographic (age, gender,
BMI, alcohol consumption, smoking, employment and
marital status), clinical (tender and swollen joint counts,
PGA-VAS, treatment received), laboratory (RF status,
anti-CCP status, ESR and CRP) and disease-related
indices (HAQ). For depression and anxiety scores at 6
months and 12 months, baseline depression and anxiety
scores were also used as independent variables. Collinear-
ity diagnostics, calculating variance inflation factor, were
run for all models. Independence of observations were
checked using Durbin-Watson test. Homoscedasticity was
also checked. Statistical analysis was performed using
GraphPad Prism 5.00 (Inc. La Jolla, CA, USA) and SPSS
21.0 (Armonk, NY: IBM Corp, USA).
RESULTS
Patient characteristics
Data from 848 patients with RA were available for evalua-
tion at baseline. Most of the patients (70.0%) were females
and their mean±SD age was of 58.27±13.71 years. Their
mean±SDDAS28, at baseline, was 4.95±1.41. Baseline char-
acteristics and treatment received for RA during the first
12 months of follow-up time are presented in table 1.
At baseline, 81 patients were already treated with psycho-
tropic drugs (eg, serotonin-norepinephrine reuptake inhi-
bitors). During the first 6 and 12months of follow-up, only
10 and 4 additional patients were commenced on medica-
tion for mood disorders.
At 6 months and at 12 months, 691 and 618 RA partici-
pants, respectively, were available for evaluation. Compar-
ing participants who continued their follow-up and those
who did not, at the 6-month and/or 12-month time-
points, there were no significant differences in either
the percentages of patients with baseline anxiety or
depression (at 6 months; anxiety: p=0.736, depression:
p=0.178 and at 12 months; anxiety: p=0.168, depression
p=0.157) or in the baseline anxiety or depression scores.
Prevalence of anxiety and depression over time
Frequency of anxiety and depression at baseline in early
RA were higher than in healthy individuals (anxiety:
19.0% vs 1.7%, p=0.0002; depression: 12.2% vs 1.7%,
p=0.009) and displayed an improving trend, over time.
In fact, prevalence of anxiety and depression at 6 months
was 15% and 9.7% and at 12 months, 13.4% and 8.1%,
respectively (figure 1A). Anxiety and depression HADS
scores were also highest at baseline and were decreased at
6 months and 12 months. Median (interquartile range—
IQR) scores at baseline, 6 months and 12 months for
anxiety were: 6.0 (3.0–9.0), 5.0 (2.0–8.0), 4.0 (1.8–8.0),
respectively, and for depression were: 5.0 (2.0–8.0), 3.0
(1.0–7.0) and 3.0 (1.0–6.0), respectively. All Wilcoxon
matched paired tests (6 months and 12 months, com-
pared to baseline) are statistically significant (p<0.0001)
(figure 1B,C). Separate subgroup analysis of the 81
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patients who were already treated with psychotropic
drugs at baseline indicated that the improving trend for
both anxiety and depression was also observed in this
group. However, statistical significance was only reached
for comparisons between baseline and 12months (online
supplemental figure 1). In general, the internal consis-
tency of the anxiety and depression scales was good.
Cronbach’s alpha at baseline, 6 months and 12 months
for depression were: 0.834, 0.860 and 0.855, and for anxi-
ety were: 0.865, 0.888 and 0.892, respectively.
Association of anxiety and depression with RA disease activity
Anxiety and depression scores were significantly positively
correlated with DAS28 disease activity scores at all time-
points (online supplemental figure 2). Correlations were
weaker for anxiety compared to those observed for depres-
sion scores. In detail, results were as follows: for anxiety;
baseline (p<0.0001, r=0.187), 6 months (p<0.0001,
r=0.299), 12 months (p<0.0001, r=0.332) and for depres-
sion; baseline (p<0.0001, r=0.333), 6 months (p<0.0001,
r=0.401), 12 months (p<0.0001, r=0.454). A separate ana-
lysis examining the association between anxiety and
depression scores with disease activity in the subgroup of
patients who were already on treatment with psychotropic
drugs at baseline (n=81) showed similar findings.
Furthermore, baseline anxiety and depression scores
correlated with DAS28 scores at 6 months and 12 months
(online supplemental figure 3). For baseline anxiety; 6
months (p<0.0001, r=0.230), 12 months (p<0.0001,
r=0.217) and for baseline depression; 6 months
(p<0.0001, r=0.265), 12 months (p<0.0001, r=0.217).
Change (final–baseline values) in the anxiety and depres-
sion scores of the patients correlated with change in
DAS28 scores at both 6 months and 12 months (online
supplemental figure 4). For anxiety; 0–6 months
(p=0.001, r=0.160), 0–12 months (p<0.0001, r=0.255)
and for depression; 0–6 months (p<0.0001, r=0.291),
0–12 months (p<0.0001, r=0.368). It should be noted
that correlation of change in anxiety scores with changes
in DAS28 at 6 months was relatively weak.
Associations with demographic, clinical and biochemical
measures of RA
The demographic, clinical and biochemical features asso-
ciated with anxiety and depression in the univariable
analyses, at the three time-points examined, are pre-
sented in tables 2 and 3.
Notably, analysing further the association of CRP with
depression (but not anxiety) at all time-points, we found
that change (final–baseline values) in CRP levels also
correlated with change in depression scores at all time-
points (0–6 months; P<0.0001, r=0.185 and 0–12 months;
P<0.0001, r=0.302).
Multivariable linear regression analysis largely con-
firmed results from univariable analyses and are pre-
sented in table 4 (only parameters that were statistically
significant for at least one time-point are presented). The
anxiety score at baseline was correlated with younger age
andHAQ score (higherHAQmeaning greater disability).
At 6 months and 12 months, the anxiety score was asso-
ciated with baseline anxiety score, lower BMI and higher
current HAQ score and PGA-VAS score. The depression
score at baseline was also associated with younger age,
HAQ and additionally with being single. At 6 months and
12 months, the depression score was associated with base-
line depression and anxiety scores as well as with male
gender (only at 6 months), current PGA-VAS scores,
HAQ scores and CRP levels.
DISCUSSION
Depression and anxiety are important comorbidities in RA
and are associated with less favourable disease outcomes
Table 1 Baseline characteristics of the rheumatoid arthritis
patients included in the analysis
Characteristic n=848
Demographic
Age (years) (mean±SD) 58.27±13.71
Female gender, n (%) 594 (70.0)
Smoking (current), n (%) 232 (27.4)
Alcohol consumption (current), n (%) 477/836 (57.1)
Weight (kg), (mean±SD) 78.14±17.13
Body Mass Index (kg/m2), (mean±SD) 28.25±5.76
Unemployment, n (%) 55 (6.5%)
Clinical
Tender Joints, median (IQR) 7 (1–11)
Swollen joints, median (IQR) 6 (1–14)
Patient’s global assessment (0–100 mm),
(mean±SD)
52.7±27.6
DAS28-ESR, (mean±SD) 4.95±1.41
DAS28-CRP (mean±SD) 4.86±1.33
Anxiety baseline (0–21), median (IQR) 6.0 (3.0–9.0)
Anxiety score ≥11, n (%) 161 (19.0)
Depression baseline (0–21), median (IQR) 5.0 (2.0–8.0)
Depression score ≥11, n (%) 103 (12.2)
Laboratory
RF positive, n (%) 348/541 (64.3)
Anti-CCP positive, n (%) 496/713 (69.6)
ESR (mm/hr), (mean±SD) 31.2±24.3
CRP (mg/l), (mean±SD) 26.5±35.5
Treatment*
Methotrexate, n (%) 596/699 (85.3)
Sulfasalazine, n (%) 337/699 (48.2)
Hydroxychloroquine, n (%) 336/699 (48.1)
Leflunomide, n (%) 5/699 (0.71)
Steroids, by mouth, n (%) 61/699 (8.7)
Steroids, intramuscularly, n (%) 515/699 (73.7)
Biologic drugs, n (%) 32/699 (4.6)
*Treatment received during the 12 months follow-up time. n, num-
ber; Kg, kilogram; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; RF, rheumatoid factor; mm,millimetres; hr, hour;
CCP, citrullinated peptide; mg, milligrams; l, litre.
Rheumatoid arthritis
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and reduced quality of life. The prevalence of depression in
our cohort was 13%. The reported frequency of depression
in published RA studies ranges between 13% and 56%.9 10
However, investigators examining psychological comorbid-
ities in RA have used different tools to assess this, making it
difficult to compare between studies. Our study used
HADS, which is highly reliable in the detection of depres-
sion in RA.11 A meta-analysis estimated that depression,
measured by HADS, occurred in 14.8% of RA patients.10
Anxiety is even more frequent than depression in both our
cohort (19%) and the published literature (25–46%).1 3
It is generally recognised that depression and anxiety
scores in RA decrease over time, which was also observed
in our cohort over the first 12 months following
diagnosis.12 13 The reasons for this are currently unclear
but several parameters (eg, better control of RA, less
inflammation) might contribute. As also observed in our
study, depression score is associated with RA disease
activity,13 although the direction of this relationship has
not been defined14 and causality cannot be inferred from
observational studies. Of note, correlations between dis-
ease activity and anxiety scores were weaker compared to
that recorded for depression scores.
Several studies report that baseline depression and
anxiety levels in RA are associated with decreased like-
lihood of achieving remission,1 3 4 although others have
not found this.2 On the other hand, studies in early RA
report that higher joint counts at baseline are associated
with increased depression at month 6.13 Another study
suggested that the HAQ score was the most important
predictor of psychological stress in early RA,12 with
a variety of other demographic and socio-economical
features like occupation and family income to be asso-
ciated with depression and anxiety in RA.12 In our study,
univariate analyses identified a number of factors asso-
ciated with HADS anxiety or depression scores at all time-
points including baseline depression and anxiety scores,
unemployment, being single, younger age, HAQ score
and increased disease activity measures.
Multiple linear regression analysis indicated that cur-
rent HAQ scores and baseline depression and anxiety
scores were the strongest predictors of depression and
anxiety scores. The association betweenHAQ and depres-
sion is consistent with findings from another study using
data from SERA cohort, which reported that functional
disability at 1-year after RA diagnosis was predicted by
depression and anxiety among other factors.15 Similarly,
another study examining predictors of depression in
a multi-ethnic RA cohort showed that higher HAQ scores
were associated with depression.9 Furthermore, in the
multivariable analysis in our study, CRP and PGA-VAS
were the only measures of disease activity assessed by
DAS28 associated with depression.
Notably, CRP was associated with depression but not
anxiety at all time-points in univariate analysis and at 6
months and 12 months in the multivariable analysis, sug-
gesting a close relationship between inflammation and
depression. This is consistent with a previous cross-
sectional study, which reported that CRP was significantly
correlated with depression levels in RA.16 Another study
of RA patients with DAS28≥3.2 and disease duration
between 3months and 2 years reported higher CRP levels
at baseline in patients who had depression compared to
those who did not.1
There appears to be a complex interplay between
depression and RA, with shared inflammatory pathways
postulated.17 It has been suggested that the aberrant
immune responses in RA could cause alterations in the
central nervous system via neuronal and humoral
pathways.17 Notably, Schrepf et al18 have demonstrated
how chronic inflammation in RA has an impact on the
brain. Higher peripheral inflammation was consistently
correlated with neural connectivity patterns, particu-
larly inferior parietal lobule and medial prefrontal cor-
tex over a 6-month period. The RA-depression
immunobiological axis is evidenced by various data.
For example, in RA blockade of systemic TNF has
beneficial effects on centrally mediated behaviours
including mood.19 Further, anti-TNF therapy in RA
acutely alters fMRI brain activation.20 21 This aligns
with significant overall improvement in well-being,
which patients can report often in advance of any
objective improvement in their peripheral joint
inflammation for example, swollen joints. Said that,
Figure 1 (A) Prevalence of anxiety and depression measured by hospital anxiety and depression scale (HADS) in early
rheumatoid arthritis over time from baseline (cut-off ≥11 for both). Longitudinal HADS anxiety (B) and depression (C) scores.
Bars and lines represent mean and SEM, respectively. All Wilcoxon matched paired test (6 months and 12 months, compared to
baseline are statistically significant, p<0.0001).
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as mentioned earlier, in the multiple regression analy-
sis of our study, depression was associated with CRP
and PGA-VAS but not with tender or swollen joints
count. Our data, especially those showing the
relationship between CRP and depression over time
support this peripheral blood-neural network link in
RA. It also provides a supportive perspective on the
increasingly compelling data implicating the immune-
Table 2 Univariable analysis. Variables associated with anxiety and/or depression scores at baseline, month 6 and month 12.
All variables are at baseline unless otherwise indicated by ¶. Significant values are highlighted in bold
Anxiety score
Baseline 6 months 12 months
Categorical factors P value P value P value
Female gender 0.002 0.212 0.214
Smoking 0.124 0.008 0.039
Unemployment* 0.001 <0.0001 <0.0001
Marital status† 0.04 0.004 0.01
Continuous variables R P value r P value r P value
Age −0.187 <0.0001 −0.158 <0.0001 −0.131 0.001
BMI 0.005 0.897 −0.044 0.289 −0.084 0.044
Anxiety baseline NA NA 0.691 <0.0001 0.632 <0.0001
Depression baseline 0.681 <0.0001 0.507 <0.0001 0.443 <0.0001
Tender joint count (0–28)¶ 0.169 <0.0001 0.314 <0.0001 0.306 <0.0001
Swollen joint count (0–28)¶ 0.011 0.759 0.161 <0.0001 0.184 <0.0001
Patient global VAS‡,¶ 0.210 <0.0001 0.397 <0.0001 0.387 <0.0001
HAQ¶ 0.339 <0.0001 0.409 <0.0001 0.446 <0.0001
Depression score
Baseline 6 months 12 months
Categorical factors P value P value P value
Smoking 0.343 0.021 0.002
Unemployment 0.001 <0.0001 <0.0001
Marital status 0.008 0.007 0.03
Anti-CCP negative 0.013 0.431 0.900
Glucocorticoids NA 0.017** 0.005††
Continuous variables R P value r P value r P value
Age −0.101 0.004 −0.028 0.494 −0.012 0.770
BMI 0.075 0.037 0.051 0.224 0.058 0.183
Alcohol units§ −0.107 0.002 −0.037 0.332 −0.057 0.160
Anxiety baseline 0.681 <0.0001 0.488 <0.0001 0.423 <0.0001
Depression baseline NA NA 0.602 <0.0001 0.519 <0.0001
Tender joint Count (0–28)¶ 0.263 <0.0001 0.361 <0.0001 0.388 <0.0001
Swollen joint Count (0–28)¶ 0.117 0.0007 0.265 <0.0001 0.276 <0.0001
Patient global VAS¶ 0.328 <0.0001 0.500 <0.0001 0.522 <0.0001
HAQ¶ 0.541 <0.0001 0.594 <0.0001 0.609 <0.0001
ESR¶ 0.116 0.016 0.077 0.128 0.130 0.029
CRP¶ 0.163 <0.0001 0.152 <0.0001 0.112 0.004
*ANOVA test, reference group employed and retired individuals.
†Married or living with partner compared to individuals who are single.
‡Used for DAS28 calculation.
§Average alcohol units/week.
¶At time point of interest.
**Oral.
††Intramuscular. BMI, bodymass index; NA, not applicable; CCP, cyclic citrullinated peptide; DAS, disease activity score; VAS, visual analogue
scale; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. Benjamini-Hochberg correction
did not affect the statistical significance of the reported values at any of the time-points examined. See table 3 for more details about categorical
variables.
Rheumatoid arthritis
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inflammatory response in some aspects of the patho-
physiology of mental disorders17 notably major depres-
sive disorder.22–24
Herein, we show, as previously reported,13 that anxiety
is highly prevalent in early RA. In our study, patient global
VAS correlated with anxiety levels, which could partially
explain the association between anxiety and worse disease
activity outcomes in RA.25 However, in contrast to what we
observed for depression in our cohort (as outlined
above), anxiety was not associated with CRP, neither in
Table 3 Anxiety and depression scores for categorical variables presented in table 2
Anxiety
Baseline 6 months 12 months
Factors mean±SD mean±SD mean±SD
Female/Male 6.8±4.3/5.6±4.5 5.7±4.4/5.4±4.6 5.3±4.4/4.7±4.3
Smokers/Non-smokers 6.8±4.5/6.3±4.4 6.4±4.8/5.3±4.3 5.9±4.7/4.9±4.2
Unemployed/Employed or Retired 9.1±5.0/6.4±4.4 or 5.9±4.2 8.6±5.7/5.6±4.2 or 5.0±4.3 8.6±5.6/5.1±4.2 or 4.7±4.2
Married-partner/single 6.1±4.2/6.9±4.7 5.2±4.1/6.5±5.0 4.8±4.1/5.9±4.8
Depression
Baseline 6 months 12 months
Factors mean±SD mean±SD mean±SD
Smokers/Non-smokers 5.8±3.8/5.5±3.9 5.2±4.1/4.4±3.8 5.2±4.2/3.9±3.6
Unemployed/Employed or Retired 7.7±4.6/5.6±3.9 or 5.3±3.7 7.5±4.4/4.3±4.0 or 4.4±3.4 7.9±5.1/3.9±3.8 or 4.0±3.4
Married-partner/single 5.3±3.5/6.3±4.4 4.3±3.8/5.2±4.2 4.0±3.6/4.8±4.0
Anti-CCP (–)/Anti-CCP (+) 6.20±3.98/5.39±3.72 4.7±3.8/4.5±3.9 4.2±3.8/4.2±3.8
Glucocorticoids (Yes/No) NA 5.3±3.9/4.4±3.9 4.4±3.9/3.4±3.5
Statistically significant differences are shown in bold. Respective p values are presented in table 2.
Table 4 Multivariable linear regression analysis. Variables associating with high anxiety and/or depression scores at baseline,
month 6 and month 12. All variables at baseline unless otherwise indicated by‡
Anxiety score
Baseline 6 months 12 months
Covariates P value Beta P value Beta P value Beta
Age 0.001 −0.217 0.669 −0.024 0.960 −0.003
BMI 0.669 −0.020 0.015 −0.097 0.001 − 0.141
Anxiety baseline NA NA <0.0001 0.609 <0.0001 0.555
Patient global VAS*,‡ 0.261 0.061 0.008 0.135 0.009 0.139
HAQ‡ <0.0001 0.307 0.006 0.146 0.001 0.208
Depression score
Baseline 6 months 12 months
Covariates P value Beta P value Beta P value Beta
Age 0.029 −0.128 0.477 0.039 0.108 −0.074
Gender 0.392 0.039 0.016 −0.689 0.153 −0.436
Marital status† 0.022 0.097 0.974 −0.001 0.716 0.015
Baseline depression score NA NA <0.0001 0.352 <0.0001 0.303
Baseline anxiety score NA NA 0.002 0.165 0.04 0.121
Patient global VAS‡ 0.101 0.082 0.012 0.125 0.010 0.136
HAQ‡ <0.001 0.486 <0.0001 0.327 <0.0001 0.372
CRP levels‡ 0.508 0.034 0.009 0.133 0.003 0.151
*Used for DAS28 calculation.
†Married or living with partner compared to individuals who are single.
‡At time point of interest. BMI, body mass index; NA, not applicable; VAS, visual analogue scale; HAQ, health assessment questionnaire; CRP,
C-reactive protein.
Significant values are shown in bold.
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univariate nor in multivariable analysis. The reasons for
this are not clear and merit further investigation. It
should also be noted that ‘anxiety’ encompasses
a heterogenous spectrum of symptoms, ranging from
contextual physiological anxiety through to anxiety
disorders,26 with some but not others associated with
some degree of inflammation.27 A more focused analysis
might reveal whether there is an ‘anxiety phenotype’ in
RA that is possibly linked with inflammation.
The inverse correlation between BMI and anxiety (but
not depression) levels at 6 and 12 months in our study is
not surprising, considering that large population studies
have shown a U-shape relationship between anxiety and
BMI.28 Data from the Rochester Epidemiology Project
indicate that anxiety is increased in underweight and
obese, but not overweight, people. This association was
more pronounced in females.28.Finally, in our early RA
cohort, baseline anxiety levels were found to be signifi-
cantly associated with subsequent anxiety scores, highlight-
ing that anxiety should also be considered in the treatment
plan of patients with RA, from the early stages of disease.
Many studies examining psychological comorbidities in
RA typically focus on depressive symptomatology and dis-
regard anxiety or describe the psychological burden with-
out distinguishing between depression and anxiety.
However, as shown here, there are differences between
depression and anxiety, at least in terms of the associating
factors in RA, further reinforcing the notion that they
should be assessed separately.
We acknowledge that our study has certain limita-
tions. First, consistent with the design of this inception
cohort, no data are available for depression, anxiety or
disease activity at time-points between baseline and the
6 months and 12 months visits. Given the stable trend
of our results, we speculate that it is unlikely that an
important finding would have been missed. Similarly,
limited data were available for patients followed-up for
a longer time period. These, however, are continu-
ously recorded and will be analysed in future studies.
Furthermore, the number of healthy individuals is
small compared that of RA patients and there may be
some differences in the performance of the HADS
questionnaire between healthy and RA individuals.
Therefore, the differences between these two groups
should be interpreted with caution. Finally, although
some of the findings have been shown by other studies
as well, our early RA inception cohort is one of the
largest, examining longitudinally mental health disor-
ders, with a validated tool in these patients.
In conclusion, our study indicates that clinicians should
be alert to neuro-psychiatric comorbidity in RA from the
earliest stages of the disease when the prevalence and
levels of depression and anxiety appear to be highest.
While depression and anxiety have been shown to have
a negative impact on outcomes in RA, it remains to be
determined whether more intense screening and treat-
ment for psychiatric comorbidities, especially in some
subgroups of patients (eg, those with high CRP, high
HAQ scores) can improve outcomes. Our results also
highlight again the link between inflammation and
depressive symptomatology. The intertwining of these
conditions points to potential common pathophysiology
thus opening the possibility of greatermechanistic under-
standing and thus greater therapeutic opportunity.
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